The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 30, Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical for short) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Construction Investment International is its sole sponsor. The company submitted its listing to the Hong Kong Stock Exchange on January 22, 2026. According to the prospectus, Bangshun Pharmaceutical is a biotechnology company in the commercialization stage, focusing on the discovery, development and commercialization of innovative treatments for cancer and autoimmune diseases. The company has established a product pipeline composed of two core products and five pre-clinical drug candidates. In terms of clinical progress, bezepitinib is the number one JAK inhibitor used to treat PV in China and the number one JAK inhibitor in the world for ET. In terms of clinical progress, one of the company's core products, CX1440, is one of the top three BTK inhibitors used to treat ITP in the world and one of the top two BTK inhibitors used to treat CU and AIHA in the world.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 30, Hangzhou Bangshun Pharmaceutical Co., Ltd. (Bangshun Pharmaceutical for short) submitted a listing application to the main board of the Hong Kong Stock Exchange, and CITIC Construction Investment International is its sole sponsor. The company submitted its listing to the Hong Kong Stock Exchange on January 22, 2026. According to the prospectus, Bangshun Pharmaceutical is a biotechnology company in the commercialization stage, focusing on the discovery, development and commercialization of innovative treatments for cancer and autoimmune diseases. The company has established a product pipeline composed of two core products and five pre-clinical drug candidates. In terms of clinical progress, bezepitinib is the number one JAK inhibitor used to treat PV in China and the number one JAK inhibitor in the world for ET. In terms of clinical progress, one of the company's core products, CX1440, is one of the top three BTK inhibitors used to treat ITP in the world and one of the top two BTK inhibitors used to treat CU and AIHA in the world.